Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report

Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report

Immune-related adverse events (irAEs) following treatment with immune checkpoint inhibitors (ICIs) can affect almost any organ systems. Multiple-organs irAEs are a rare occurrence which makes its management and treatment very challenging. This is a case report of a 71-year-old man with advanced non-...

Full description

Bibliographic Details
Main Authors:	Chao Deng, Meng Yang, Hong Jiang, Renbin Wang, Zhaojun Yang, Hongliang Sun, Huijuan Cui
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Series:	Frontiers in Oncology
Subjects:	immune checkpoint inhibitors (ICIs) tislelizumab immune-related adverse events (irAEs) non-small cell lung cancer (NSCLC) programmed cell death-1(PD-1)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.664809/full

Similar Items

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
by: Peng Song, et al.
Published: (2020-09-01)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
by: Xiaoyan Si, et al.
Published: (2020-02-01)

A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma
by: Satoshi Tanaka, et al.
Published: (2020-01-01)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
by: Donghui Wang, et al.
Published: (2021-03-01)

Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer
by: Yuriko Ueki, et al.
Published: (2020-09-01)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
by: Ryo Sato, et al.
Published: (2019-05-01)

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes
by: Charline Lafayolle de la Bruyère, et al.
Published: (2021-05-01)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
by: Neil J. Shah, et al.
Published: (2019-12-01)

Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition
by: Samy Hakroush, et al.
Published: (2021-01-01)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
by: Vivek Kumar, et al.
Published: (2017-02-01)

Atezolizumab-induced bilateral anterior uveitis: A case report
by: Tsuyoshi Mito, et al.
Published: (2021-12-01)

Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
by: Agnese Paderi, et al.
Published: (2021-02-01)

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy
by: Xiaowei Liu, et al.
Published: (2020-03-01)

Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer
by: James Luke Godwin, et al.
Published: (2017-05-01)

Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review
by: Yoest JM
Published: (2017-10-01)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
by: Wolfgang M. Brueckl, et al.
Published: (2020-12-01)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
by: Lili Cheng, et al.
Published: (2021-07-01)

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer
by: Wanting Hou, et al.
Published: (2021-03-01)

Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment
by: Xiaohu Zheng, et al.
Published: (2021-05-01)

A Review of Immune-Mediated Adverse Events in Melanoma
by: Lucy Boyce Kennedy, et al.
Published: (2019-07-01)

A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation
by: Tomoyo Oguri, et al.
Published: (2021-01-01)

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients
by: Koichi Saruwatari, et al.
Published: (2019-01-01)

Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events
by: Heinz Läubli, et al.
Published: (2018-05-01)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
by: Yuan Hong, et al.
Published: (2021-03-01)

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma
by: Qijun Li, et al.
Published: (2021-03-01)

Anti-PD-1 Therapy Does Not Influence Hearing Ability in the Most Sensitive Frequency Range, but Mitigates Outer Hair Cell Loss in the Basal Cochlear Region
by: Judit Szepesy, et al.
Published: (2020-09-01)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
by: Jiashuo Chao, et al.
Published: (2021-03-01)

Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options
by: Carmen Portenkirchner, et al.
Published: (2021-04-01)

Patterns of immunotherapy-induced pneumonitis in patients with non-small-cell lung cancer: a case series
by: Sarah Picard, et al.
Published: (2021-07-01)

Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors
by: Dan Zhao, et al.
Published: (2021-05-01)

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
by: Chiao-En Wu, et al.
Published: (2020-10-01)

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
by: Pierpaolo Correale, et al.
Published: (2020-08-01)

Prognostic significance of the radiologic features of pneumonitis induced by anti‐PD‐1 therapy
by: Satoshi Watanabe, et al.
Published: (2020-05-01)

Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection
by: Cheng Zhou, et al.
Published: (2019-02-01)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
by: Cinzia Vetrei, et al.
Published: (2021-06-01)

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
by: Biagio Ricciuti, MD, et al.
Published: (2020-11-01)

Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report
by: Yoshitsugu Narumi, et al.
Published: (2018-01-01)

Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors
by: Lorena Arribas, et al.
Published: (2021-06-01)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
by: Maria A Papadaki, et al.
Published: (2020-06-01)

Impact of BMI on Survival Outcomes of Immunotherapyin Solid Tumors: A Systematic Review
by: Alice Indini, et al.
Published: (2021-03-01)